Welcome to LookChem.com Sign In|Join Free

CAS

  • or
CYCLO (ARG-GLY-ASP-D-PHE-LYS) is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

161552-03-0 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 161552-03-0 Structure
  • Basic information

    1. Product Name: CYCLO (ARG-GLY-ASP-D-PHE-LYS)
    2. Synonyms: CYCLO(-RGDFK);CYCLO (ARG-GLY-ASP-D-PHE-LYS);cyclo (Arg-Gly-Asp-Phe-Lys);c(RGDfK);Cyclic RGDFK peptide;Cyclo(L-arginylglycyl-L-alpha-aspartyl-D-phenylalanyl-L-lysyl);Cyclo(-Arg-Gly-Asp-D-Phe-Lys) Trifluoroacetate salt
    3. CAS NO:161552-03-0
    4. Molecular Formula: C27H41N9O7
    5. Molecular Weight: 603.67
    6. EINECS: N/A
    7. Product Categories: peptide
    8. Mol File: 161552-03-0.mol
  • Chemical Properties

    1. Melting Point: 191℃ (decomposition)
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.47±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: ≥30.19 mg/mL in DMSO; insoluble in EtOH; ≥59.2 mg/mL in H2O
    9. PKA: 4.01±0.10(Predicted)
    10. CAS DataBase Reference: CYCLO (ARG-GLY-ASP-D-PHE-LYS)(CAS DataBase Reference)
    11. NIST Chemistry Reference: CYCLO (ARG-GLY-ASP-D-PHE-LYS)(161552-03-0)
    12. EPA Substance Registry System: CYCLO (ARG-GLY-ASP-D-PHE-LYS)(161552-03-0)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 161552-03-0(Hazardous Substances Data)

161552-03-0 Usage

Biological Activity

in one study where this peptide was labeled with 125i, it was found to bind specifically and with high affinity to αvβ3 receptors on neovascular blood vessel sections of different major human cancers. the integrin alpha(iib)beta(3)-specific cyclic hexapeptide contains an arg-gly-asp (rgd) sequence.

Check Digit Verification of cas no

The CAS Registry Mumber 161552-03-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,1,5,5 and 2 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 161552-03:
(8*1)+(7*6)+(6*1)+(5*5)+(4*5)+(3*2)+(2*0)+(1*3)=110
110 % 10 = 0
So 161552-03-0 is a valid CAS Registry Number.

161552-03-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[(2S,5R,8S,11S)-8-(4-aminobutyl)-5-benzyl-11-[3-(diaminomethylideneamino)propyl]-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentazacyclopentadec-2-yl]acetic acid

1.2 Other means of identification

Product number -
Other names c(D-Phe-Lys-Arg-Gly-Asp)

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:161552-03-0 SDS

161552-03-0Synthetic route

C42H51ClN10O11

C42H51ClN10O11

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In methanol; acetic acid at 20℃; for 18h;100%
Fmoc-Asp(OAll)-Pol

Fmoc-Asp(OAll)-Pol

N-(fluoren-9-ylmethoxycarbonyl)glycine
29022-11-5

N-(fluoren-9-ylmethoxycarbonyl)glycine

Fmoc-Lys(tert-butoxycarbonyl)
71989-26-9

Fmoc-Lys(tert-butoxycarbonyl)

Fmoc-D-Phe-OH
86123-10-6

Fmoc-D-Phe-OH

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Stage #1: Fmoc-Asp(OAll)-Pol
Stage #2: N-(fluoren-9-ylmethoxycarbonyl)glycine
Stage #3: Fmoc-Lys(tert-butoxycarbonyl); Fmoc-D-Phe-OH; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine Further stages;
43%
2-chlorotrityl resin

2-chlorotrityl resin

Fmoc-dPhe-OH

Fmoc-dPhe-OH

Fmoc-(tBu)Asp-OH
71989-14-5

Fmoc-(tBu)Asp-OH

Nα-Fmoc-Nε-Trt-Lys
111061-54-2

Nα-Fmoc-Nε-Trt-Lys

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Stage #1: H-Gly-(2-Cl)-Trt-pol; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine With N-ethyl-N,N-diisopropylamine; [ethyl cyano(hydroxyimino)acetato-O2]tri-1-pyrrolidinylphosphonium hexafluorophosphate at 20℃; for 1h; 2-CT Cl resin;
Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 0.1h;
Stage #3: Fmoc-dPhe-OH; Fmoc-(tBu)Asp-OH; Nα-Fmoc-Nε-Trt-Lys Further stages;
43%
2-chlorotrityl resin

2-chlorotrityl resin

Fmoc-dPhe-OH

Fmoc-dPhe-OH

Fmoc-(tBu)Asp-OH
71989-14-5

Fmoc-(tBu)Asp-OH

Fmoc-Lys(OAc)-OH
159766-56-0

Fmoc-Lys(OAc)-OH

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Stage #1: H-Gly-(2-Cl)-Trt-pol; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine With N-ethyl-N,N-diisopropylamine; [ethyl cyano(hydroxyimino)acetato-O2]tri-1-pyrrolidinylphosphonium hexafluorophosphate at 20℃; for 1h; 2-CT Cl resin;
Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 0.1h;
Stage #3: Fmoc-dPhe-OH; Fmoc-(tBu)Asp-OH; Fmoc-Lys(OAc)-OH Further stages;
43%
C45H67N9O10S
388633-54-3

C45H67N9O10S

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With chlorotriisopropylsilane; water; trifluoroacetic acid for 2h;
Fmoc-(tBu)Asp-OH
71989-14-5

Fmoc-(tBu)Asp-OH

Fmoc-D-Phe-OH
86123-10-6

Fmoc-D-Phe-OH

Alloc-L-Lys(N-Fmoc)-OH
186350-56-1

Alloc-L-Lys(N-Fmoc)-OH

R(Pmc)-G linear peptide bound to resin

R(Pmc)-G linear peptide bound to resin

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multistep reaction;
Fmoc-(tBu)Asp-OH
71989-14-5

Fmoc-(tBu)Asp-OH

Fmoc-Asn-OHFmoc-Leu-OH

Fmoc-Asn-OHFmoc-Leu-OH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: Pd(PPh3)4; PhSiH3
2: TFA; triisopropylsilane; water / 2 h
View Scheme
Fmoc-D-Phe-OH
86123-10-6

Fmoc-D-Phe-OH

bis-1,4-aminomethylcyclohexane on chlorotrityl resin

bis-1,4-aminomethylcyclohexane on chlorotrityl resin

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: Pd(PPh3)4; PhSiH3
2: TFA; triisopropylsilane; water / 2 h
View Scheme
(S)-6-allyloxycarbonylamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid
146982-27-6

(S)-6-allyloxycarbonylamino-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: Pd(PPh3)4; PhSiH3
2: TFA; triisopropylsilane; water / 2 h
View Scheme
cyclo(-D(tBu)-f-K(Aloc)-R(Pmc)-G-)
343312-39-0

cyclo(-D(tBu)-f-K(Aloc)-R(Pmc)-G-)

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: Pd(PPh3)4; PhSiH3
2: TFA; triisopropylsilane; water / 2 h
View Scheme
C39H56N10O11
1035105-00-0

C39H56N10O11

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
for 2h; UV-irradiation;
C74H84N9O12PolS

C74H84N9O12PolS

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With chlorotriisopropylsilane; trifluoroacetic acid In dichloromethane at 20℃; for 3h; solid phase reaction;0.45 mg
C39H56N10O11
1035105-00-0

C39H56N10O11

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
for 1.5h; Irradiation;92 %Chromat.
N-(fluoren-9-ylmethoxycarbonyl)glycine
29022-11-5

N-(fluoren-9-ylmethoxycarbonyl)glycine

Fmoc-Lys(tert-butoxycarbonyl)
71989-26-9

Fmoc-Lys(tert-butoxycarbonyl)

Fmoc-D-Phe-OH
86123-10-6

Fmoc-D-Phe-OH

N-alpha-(9-fluorenylmethyloxycarbonyl)-L-aspartic acid beta-allyl ester
146982-24-3

N-alpha-(9-fluorenylmethyloxycarbonyl)-L-aspartic acid beta-allyl ester

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Stage #1: N-alpha-(9-fluorenylmethyloxycarbonyl)-L-aspartic acid beta-allyl ester With N-ethyl-N,N-diisopropylamine In dichloromethane for 3h; 2-chlorotrityl chloride polystyrene resin;
Stage #2: With piperidine In 1-methyl-pyrrolidin-2-one for 0.416667h;
Stage #3: N-(fluoren-9-ylmethoxycarbonyl)glycine; Fmoc-Lys(tert-butoxycarbonyl); Fmoc-D-Phe-OH; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine Further stages;
c[R]GDfK

c[R]GDfK

A

7-(diethylamino)-4-(hydroxymethyl)-2H-chromen-2-one
54711-38-5

7-(diethylamino)-4-(hydroxymethyl)-2H-chromen-2-one

B

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With water In aq. buffer pH=7.4; Irradiation;
C21H29BrN8O8

C21H29BrN8O8

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 9 steps
1.1: dichloromethane / 20 °C
2.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
2.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
3.1: hydrogenchloride / 1,4-dioxane / 20 °C
4.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
4.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
5.1: hydrogenchloride / 1,4-dioxane / 20 °C
6.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
6.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
7.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
8.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
9.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C16H21BrN8O6*C2HF3O2

C16H21BrN8O6*C2HF3O2

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 8 steps
1.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
1.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
2.1: hydrogenchloride / 1,4-dioxane / 20 °C
3.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
3.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
4.1: hydrogenchloride / 1,4-dioxane / 20 °C
5.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
5.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
6.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
7.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
8.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C35H46BrClN10O11

C35H46BrClN10O11

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1.1: hydrogenchloride / 1,4-dioxane / 20 °C
2.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
2.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
3.1: hydrogenchloride / 1,4-dioxane / 20 °C
4.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
4.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
5.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
6.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
7.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C30H38BrClN10O9*ClH

C30H38BrClN10O9*ClH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
1.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
2.1: hydrogenchloride / 1,4-dioxane / 20 °C
3.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
3.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
4.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
5.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
6.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C44H55BrClN11O12

C44H55BrClN11O12

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1.1: hydrogenchloride / 1,4-dioxane / 20 °C
2.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
2.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
3.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
4.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
5.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C39H47BrClN11O10*ClH

C39H47BrClN11O10*ClH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1.1: N-ethyl-N,N-diisopropylamine; bis(trichloromethyl) carbonate / N,N-dimethyl-formamide; acetonitrile / 0 h / 20 °C / Flow reactor
1.2: 0 h / 20 °C / pH 8 - 9 / Flow reactor
2.1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
3.1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
4.1: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C55H66BrClN12O15

C55H66BrClN12O15

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: hydrogenchloride / 1,4-dioxane / 0.67 h / 20 °C
2: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
3: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
C50H58BrClN12O13

C50H58BrClN12O13

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: acetonitrile / 0.08 h / 20 °C / UV-irradiation; Flow reactor
2: hydrogen; palladium 10% on activated carbon / methanol; acetic acid / 18 h / 20 °C
View Scheme
Fmoc-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH

Fmoc-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: piperidine / N,N-dimethyl-formamide / 3 h / 0 - 20 °C
2: sodium hydroxide; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; benzotriazol-1-ol / N,N-dimethyl-formamide / 24 h / 20 °C / pH 8
3: trifluoroacetic acid; methyl-phenyl-thioether; chlorotriisopropylsilane; phenol / 3 h / 20 °C
View Scheme
H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH
942132-29-8

H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydroxide; (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; benzotriazol-1-ol / N,N-dimethyl-formamide / 24 h / 20 °C / pH 8
2: trifluoroacetic acid; methyl-phenyl-thioether; chlorotriisopropylsilane; phenol / 3 h / 20 °C
View Scheme
cyclized H2N-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH
545376-68-9

cyclized H2N-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-Gly-OH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With chlorotriisopropylsilane; methyl-phenyl-thioether; trifluoroacetic acid; phenol at 20℃; for 3h;
With chlorotriisopropylsilane; water; trifluoroacetic acid at 20℃; for 24h;
Gly-Arg(Pbf)-Lys(Boc)-D-Phe-Asp(OtBu)-OH

Gly-Arg(Pbf)-Lys(Boc)-D-Phe-Asp(OtBu)-OH

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydrogencarbonate; diphenyl phosphoryl azide / N,N-dimethyl-formamide / 24 h / 20 °C
2: trifluoroacetic acid; water; chlorotriisopropylsilane / 24 h / 20 °C
View Scheme
C45H67N9O13S

C45H67N9O13S

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydrogencarbonate; diphenyl phosphoryl azide / N,N-dimethyl-formamide
2: trifluoroacetic acid; chlorotriisopropylsilane / water / 2 h / 20 °C
View Scheme
C45H65N9O12S

C45H65N9O12S

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
With chlorotriisopropylsilane; trifluoroacetic acid In water at 20℃; for 2h;
C56H67ClN11O8Pol

C56H67ClN11O8Pol

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Conditions
ConditionsYield
Stage #1: C56H67ClN11O8Pol With hydrazine hydrate In N,N-dimethyl-formamide for 0.0833333h; CTC-resin;
Stage #2: With methyl-phenyl-thioether; ethane-1,2-dithiol; methoxybenzene; trifluoroacetic acid CTC-resin;
C14H21N5O7
1145938-00-6

C14H21N5O7

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C37H57N13O11
1145938-02-8

C37H57N13O11

Conditions
ConditionsYield
In dimethyl sulfoxide; acetonitrile99%
ADIBO-PEG5-N-succinimidyl ester
1378531-80-6

ADIBO-PEG5-N-succinimidyl ester

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C59H79N11O15
1415001-59-0

C59H79N11O15

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 20℃;90%
C26H39NO13
1422540-83-7

C26H39NO13

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C47H75N9O17
1422541-06-7

C47H75N9O17

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide at 20℃; for 15h; Inert atmosphere;86%
1,3-bis[4, 10-bis(carboxymethyl)-1,4,10-triaza-7-oxacyclododec-1-ylmethyl]-5-isothiocyanatobenzene hydrochloride salt

1,3-bis[4, 10-bis(carboxymethyl)-1,4,10-triaza-7-oxacyclododec-1-ylmethyl]-5-isothiocyanatobenzene hydrochloride salt

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C60H92N16O17S

C60H92N16O17S

Conditions
ConditionsYield
In aq. buffer at 20℃; for 24h; pH=9;84%
2,5-dioxopyrrolidin-1-yl (E)-3-(2-(2-(4-(dicyanomethylene)-6-methyl-4H-pyran-2-yl)vinyl)-7-(diphenylamino)-9-(2-(2-ethoxyethoxy)ethyl)-9H-fluoren-9-yl)propanoate

2,5-dioxopyrrolidin-1-yl (E)-3-(2-(2-(4-(dicyanomethylene)-6-methyl-4H-pyran-2-yl)vinyl)-7-(diphenylamino)-9-(2-(2-ethoxyethoxy)ethyl)-9H-fluoren-9-yl)propanoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C72H80N12O11

C72H80N12O11

Conditions
ConditionsYield
In N,N-dimethyl-formamide at 20℃; for 24h; Inert atmosphere;82%
6-[(2-ethylcarbamothioyl)hydrazinyl]-3-pyridinecarboxylic acid

6-[(2-ethylcarbamothioyl)hydrazinyl]-3-pyridinecarboxylic acid

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C36H51N13O8S

C36H51N13O8S

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃;80%
C52H50N12O10Si

C52H50N12O10Si

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C79H89N21O16Si

C79H89N21O16Si

Conditions
ConditionsYield
Stage #1: C52H50N12O10Si With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; for 4h;
Stage #2: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;
78%
cholesterol-tetraethylene glycol-DSC

cholesterol-tetraethylene glycol-DSC

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

cholesterol-cRGDfK

cholesterol-cRGDfK

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 16h;74%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 16h;74%
2,5-dioxopyrrolidin-1-yl pent-4-ynoate
132178-37-1

2,5-dioxopyrrolidin-1-yl pent-4-ynoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-pent-4-ynoyl-L-lysyl)
1076242-17-5

cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-N6-pent-4-ynoyl-L-lysyl)

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide70%
[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

Chloroacetic anhydride
541-88-8

Chloroacetic anhydride

cyclo[Lys(ClAc)-Arg-Gly-Asp-D-Phe]

cyclo[Lys(ClAc)-Arg-Gly-Asp-D-Phe]

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 10h;65%
6-maleimidohexanoic acid N-hydroxylsuccinimide ester
55750-63-5

6-maleimidohexanoic acid N-hydroxylsuccinimide ester

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C37H52N10O10

C37H52N10O10

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 4h;64.1%
C48H60N5O8S(1+)*I(1-)*Na(1+)

C48H60N5O8S(1+)*I(1-)*Na(1+)

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C75H99N14O14S(1+)*I(1-)*Na(1+)

C75H99N14O14S(1+)*I(1-)*Na(1+)

Conditions
ConditionsYield
Stage #1: C48H60N5O8S(1+)*I(1-)*Na(1+) With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 0.5h; Inert atmosphere;
Stage #2: With O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate In N,N-dimethyl-formamide for 3h; Inert atmosphere;
Stage #3: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 18h;
60%
2,5-dioxopyrrolidin-1-yl 3-iodobenzoate
91487-18-2

2,5-dioxopyrrolidin-1-yl 3-iodobenzoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C34H44IN9O8

C34H44IN9O8

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide for 3h;59%
C18H18N6O5

C18H18N6O5

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C41H54N14O9

C41H54N14O9

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 0.5h;57%
succinimidyl 4-formylbenzoate
60444-78-2

succinimidyl 4-formylbenzoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C35H45N9O9
1261036-91-2

C35H45N9O9

Conditions
ConditionsYield
In N,N-dimethyl-formamide for 1h; pH=7.5; aq. phosphate buffer;56%
6-[2-(phenylcarbamothioyl)hydrazinyl]-3-pyridinecarboxylic acid

6-[2-(phenylcarbamothioyl)hydrazinyl]-3-pyridinecarboxylic acid

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C40H51N13O8S

C40H51N13O8S

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃;55%
rel-(1R-4E-pS)-cyclooct-4-ene-1-yl (4-nitrophenyl) carbonate

rel-(1R-4E-pS)-cyclooct-4-ene-1-yl (4-nitrophenyl) carbonate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C36H53N9O9

C36H53N9O9

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 6h;52%
C42H48N6O10Pd

C42H48N6O10Pd

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2,3-dihydroxypropyl)amide-173-(cycloRGDfK)amide

palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2,3-dihydroxypropyl)amide-173-(cycloRGDfK)amide

Conditions
ConditionsYield
With triethylamine In 1-methyl-pyrrolidin-2-one for 1.25h;50%
2,5-dioxopyrrolidin-1-yl-6-(4-(dimethylamino)phenoxy)hexanoate
1338496-56-2

2,5-dioxopyrrolidin-1-yl-6-(4-(dimethylamino)phenoxy)hexanoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C41H60N10O9
1338496-53-9

C41H60N10O9

Conditions
ConditionsYield
With N-ethyl-N,N-diisopropylamine In water; N,N-dimethyl-formamide at 20℃;50%
[Ru(2,2′:6′,2″-terpyridine)(2,2′-bipyridine)(D-biotin)](Cl)2

[Ru(2,2′:6′,2″-terpyridine)(2,2′-bipyridine)(D-biotin)](Cl)2

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C62H74N16O9RuS(2+)*2Cl(1-)

C62H74N16O9RuS(2+)*2Cl(1-)

Conditions
ConditionsYield
Stage #1: [Ru(2,2′:6′,2″-terpyridine)(2,2′-bipyridine)(D-biotin)](Cl)2 With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-hydroxy-2,5-dioxopyrrolidine-3-sulfonic acid In dimethyl sulfoxide at 20℃; for 24h; Darkness;
Stage #2: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With triethylamine pH=7; Darkness;
50%
11-azido-3,6,9-trioxaundecanoic acid
172531-37-2

11-azido-3,6,9-trioxaundecanoic acid

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

2-((2S,5R,8S,11S)-8-(1-azido-11-oxo-3,6,9-trioxa-12-azahexadecan-16-yl)-5-benzyl-11-(3-guanidinopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid

2-((2S,5R,8S,11S)-8-(1-azido-11-oxo-3,6,9-trioxa-12-azahexadecan-16-yl)-5-benzyl-11-(3-guanidinopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)acetic acid

Conditions
ConditionsYield
Stage #1: 11-azido-3,6,9-trioxaundecanoic acid With 1-hydroxy-pyrrolidine-2,5-dione; dicyclohexyl-carbodiimide In dimethyl sulfoxide at 20℃;
Stage #2: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid In dimethyl sulfoxide at 20℃;
48.3%
[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

(3R,4R,5R,6S)-6-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid
655246-28-9

(3R,4R,5R,6S)-6-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid

C49H62N10O14

C49H62N10O14

Conditions
ConditionsYield
Stage #1: (3R,4R,5R,6S)-6-((((9H-fluoren-9-yl)methoxy)carbonylamino)methyl)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid With 1-hydroxy-pyrrolidine-2,5-dione; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide at 20℃; for 1h;
Stage #2: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 6h;
43%
5,5′,5″-(((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(1H-imidazole-2,1-diyl))tripentanoic acid

5,5′,5″-(((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(1H-imidazole-2,1-diyl))tripentanoic acid

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C114H168N36O24

C114H168N36O24

Conditions
ConditionsYield
Stage #1: 5,5′,5″-(((1,4,7-triazonane-1,4,7-triyl)tris(methylene))tris(1H-imidazole-2,1-diyl))tripentanoic acid With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 20℃; for 0.5h;
Stage #2: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid In N,N-dimethyl-formamide for 2h;
41%
C16H22Cl2N4O12Pt
1542144-06-8

C16H22Cl2N4O12Pt

C54H61N9O11Si

C54H61N9O11Si

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C89H114Cl2N20O24PtSi

C89H114Cl2N20O24PtSi

Conditions
ConditionsYield
Stage #1: C54H61N9O11Si; [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With N-ethyl-N,N-diisopropylamine In dimethyl sulfoxide at 20℃; for 0.166667h;
Stage #2: C16H22Cl2N4O12Pt In dimethyl sulfoxide at 20℃; for 24h;
40%
C49H49N3O10S2*2H3N

C49H49N3O10S2*2H3N

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C72H85N11O14S2

C72H85N11O14S2

Conditions
ConditionsYield
Stage #1: [(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide for 0.00833333h;
Stage #2: C49H49N3O10S2*2H3N In N,N-dimethyl-formamide at 20℃; for 2h; Inert atmosphere;
36%
N-succinimidyl 3-bromobenzoate

N-succinimidyl 3-bromobenzoate

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid
161552-03-0

[(2S,5R,8S,11S)-8-(4-Amino-butyl)-5-benzyl-11-(3-guanidino-propyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid

C34H44BrN9O8

C34H44BrN9O8

Conditions
ConditionsYield
With triethylamine In N,N-dimethyl-formamide for 3h;35%

161552-03-0Relevant articles and documents

Two bifunctional desferrioxamine chelators for bioorthogonal labeling of biovectors with zirconium-89

Gao,Ieritano,Chen,Dias,Rousseau,Bénard,Seimbille

, p. 5102 - 5106 (2018)

We report two bifunctional chelators, DFO-Cys and DFO-CBT, to label biovectors with zirconium-89 according to the 2-cyanobenzothiazole/1,2-aminothiol cycloaddition. Their features are high labeling yields, rapid and efficient bioconjugation, metabolically stable luciferin-based end products, and applicability to orthogonal two-step labeling of sensitive biomolecules.

Efficient Triplet-Triplet Annihilation-Based Upconversion for Nanoparticle Phototargeting

Wang, Weiping,Liu, Qian,Zhan, Changyou,Barhoumi, Aoune,Yang, Tianshe,Wylie, Ryan G.,Armstrong, Patrick A.,Kohane, Daniel S.

, p. 6332 - 6338 (2015)

High-efficiency upconverted light would be a desirable stimulus for triggered drug delivery. Here we present a general strategy to achieve photoreactions based on triplet-triplet annihilation upconversion (TTA-UC) and F?rster resonance energy transfer (FRET). We designed PLA-PEG micellar nanoparticles containing in their cores hydrophobic photosensitizer and annihilator molecules which, when stimulated with green light, would undergo TTA-UC. The upconverted energy was then transferred by FRET to a hydrophobic photocleavable group (DEACM), also in the core. The DEACM was bonded to (and thus inactivated) the cell-binding peptide cyclo-(RGDfK), which was bound to the PLA-PEG chain. Cleavage of DEACM by FRET reactivated the PLA-PEG-bound peptide and allowed it to move from the particle core to the surface. TTA-UC followed by FRET allowed photocontrolled binding of cell adhesion with green light LED irradiation at low irradiance for short periods. These are attractive properties in phototriggered systems.

Photoactivatable caged cyclic RGD peptide for triggering integrin binding and cell adhesion to surfaces

Wirkner, Melanie,Weis, Simone,San Miguel, Veronica,Alvarez, Marta,Gropeanu, Radu A.,Salierno, Marcelo,Sartoris, Anne,Unger, Ronald E.,Kirkpatrick, C. James,del Campo, Aranzazu

, p. 2623 - 2629 (2011)

We report the synthesis and properties of a photoactivatable caged RGD peptide and its application for phototriggering integrin- and cell-binding to surfaces. We analysed in detail 1) the differences in the integrin-binding affinity of the caged and uncaged forms by quartz crystal microbalance (QCM) studies, 2) the efficiency and yield of the photolytic uncaging reaction, 3) the biocompatibility of the photolysis by-products and irradiation conditions, 4) the possibility of site, temporal and density control of integrin-binding and therefore human cell attachment, and 5) the possibility of in situ generation of cell patterns and cell gradients by controlling the UV exposure. These studies provide a clear picture of the potential and limitations of caged RGD for integrin-mediated cell adhesion and demonstrate the application of this approach to the control and study of cell interactions and responses.

Design and synthesis of novel dual-cyclic RGD peptides for αvβ3 integrin targeting

Liu, Junjie,Cheng, Xiaozhong,Tian, Xiaobo,Guan, Dongliang,Ao, Jiwei,Wu, Zhimeng,Huang, Wei,Le, Zhiping

, p. 896 - 900 (2019)

The specific binding of RGD cyclic peptide with integrin αvβ3 attracts great research interest for tumor-targeting drug delivery. Herein, we designed and synthesized a series of dual-ring RGD-peptide derivatives as a drug carrier for αvβ3 targeting. Three novel peptides showed excellent cell adhesion inhibition effect, in which, P3 exhibited 7-fold enhancement in IC50 compared with cyclo(RGDfK). Drug-loaded cytotoxicity experiment and imaging experiment indicated that such dual-cyclic RGD peptides have good tumor targeting effects. This work provides a new strategy for the design of novel RGD peptides.

A Stable Precursor for Bioorthogonally Removable 3-Isocyanopropyloxycarbonyl (ICPrc) Protecting Groups

Tu, Julian,Xu, Minghao,Franzini, Raphael M.

, p. 1701 - 1706 (2020)

Studies have established 3-isocyanopropyloxycarbonyl (ICPrc) moieties as bioorthogonally removable protecting groups. However, reagents to prepare ICPrc-protected amines are unstable, which critically limits the practical implementation of this chemistry. Here we report 3-isocyanopropyl (pentafluorophenyl) carbonates as bench-stable precursors for the synthesis of ICPrc-protected primary and secondary amines. The utility of the chemistry for bioconjugation applications is demonstrated by reversibly masking a lysine residue on a bioactive peptide.

Synthesis and Biological Evaluation of Paclitaxel Conjugates Involving Linkers Cleavable by Lysosomal Enzymes and αVβ3-Integrin Ligands for Tumor Targeting

López Rivas, Paula,Ran?elovi?, Ivan,Raposo Moreira Dias, André,Pina, Arianna,Arosio, Daniela,Tóvári, József,Mez?, Gábor,Dal Corso, Alberto,Pignataro, Luca,Gennari, Cesare

supporting information, p. 2902 - 2909 (2018/06/27)

Two cyclo[DKP-RGD]-PTX (PTX = paclitaxel) and two cyclo[RGDfK]-PTX conjugates containing the Gly-Phe-Leu-Gly (GFLG) linker, which is cleavable by lysosomal enzymes, were synthesized and compared to two cyclo[DKP-RGD]-Val-Ala-PTX conjugates. The conjugates were evaluated for their ability to inhibit biotinylated vitronectin binding to the isolated αvβ3 receptor, retaining good binding affinity, in the same nanomolar range of the free ligands. Cell viability assays were performed for the six conjugates in the αvβ3+ U87 and in the αvβ3– HT29 cell lines. Loss of potency was observed for all the conjugates, attenuated by the presence of a tetraethylene glycol (PEG-4) spacer. A good Targeting Index (TI = Relative Potency in the αvβ3+ U87/Relative Potency in the αvβ3– HT29) was displayed by the conjugates, in particular by cyclo[DKP-RGD]-PEG-4-Val-Ala-PTX 9 (TI = 533). This conjugate was tested in the αvβ3+ U87 cell line in the presence of 50-fold excess free cyclo[DKP-RGD] ligand 2. In this competition experiment, a fivefold decrease of the conjugate cytotoxicity was calculated, suggesting that the conjugate is possibly internalized by an αvβ3 integrin-mediated process.

Comparison of radioiodine- or radiobromine-labeled rgd peptides between direct and indirect labeling methods

Ogawa, Kazuma,Takeda, Takuya,Yokokawa, Masaru,Yu, Jing,Makino, Akira,Kiyono, Yasushi,Shiba, Kazuhiro,Kinuya, Seigo,Odani, Akira

, p. 651 - 659 (2018/06/11)

Radiolabeled cyclic peptides containing the (Arg-Gly-Asp) RGD sequence for use in positron emission tomography (PET) imaging, single-photon emission computed tomography (SPECT) imaging, and targeted radionuclide therapy of cancer have been reported. In this study, RGD was used as a model carrier peptide for diagnosis and therapy of cancer. To evaluate the characteristics of radiohalogen-labeled peptides, several kinds of labeled RGD peptides [125I-c(RGDyK), 77Br-c(RGDyK), [125I]SIB-c(RGDfK), [77Br]SBrB-c(RGDfK), [125I]SIB-EG2-c(RGDfK), and [77Br]SBrB-EG2-c(RGDfK)] were designed, prepared, and evaluated. In these initial studies, 77Br (t1/2=57.0h) and 125I (t1/2=59.4d) were used because of their longer half-lives. Precursor peptides were synthesized using a standard 9-fluorenylmethyloxycarbonyl (Fmoc)-based solid-phase methodology. Radiolabeled peptides were prepared by chloramine-T method or conjugation of RGD peptides with [125I]N-succinimidyl 3-iodobenzoate ([125I]SIB) or [77Br]N-succinimidyl 3-bromobenzoate ([77Br]SBrB). Measurement of the partition coefficients, integrin binding assay, and biodistribution experiments in tumor-bearing mice were performed. 125I and 77Br labeling were successfully performed using similar methods, and in vitro characteristics and biodistributions were similar between the 125I-labeled and corresponding 77Br-labeled peptides. [125I]SIB- and [77Br]SBrB-conjugated RGD peptides showed higher partition coefficients, lower tumor uptakes, and higher intestinal uptake than 125I-c(RGDyK) and 77Br-c(RGDyK). [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK), which possess an ethylene glycol linker, decreased lipophilicity and uptake in intestine compared with [125I]SIB-c(RGDfK) and [77Br]SBrB-c(RGDfK), which possess no linker. However, the improvement in biodistribution of [125I]SIB-EG2-c(RGDfK) and [77Br]SBrB-EG2-c(RGDfK)] was insufficient. In conclusion, directly radiohalogenated c(RGDyK) peptides are potentially more useful for tumor imaging and therapy than indirectly radiohalogenated ones.

Application of Methyl Bisphosphine-Ligated Palladium Complexes for Low Pressure N-11C-Acetylation of Peptides

Andersen, Thomas L.,Nordeman, Patrik,Christoffersen, Heidi F.,Audrain, Hélène,Antoni, Gunnar,Skrydstrup, Troels

supporting information, p. 4549 - 4553 (2017/04/13)

A mild and effective method is described for 11C-labeling of peptides selectively at the N-terminal nitrogen or at internal lysine positions. The presented method relies on the use of specific biphosphine palladium–methyl complexes and their high reactivity towards amino-carbonylation of amine groups in the presence [11C]carbon monoxide. The protocol facilitates the production of native N-11C-acetylated peptides, without any structural modifications and has been applied to a selection of bioactive peptides.

A rapid and clean synthetic approach to cyclic peptides: Via micro-flow peptide chain elongation and photochemical cyclization: Synthesis of a cyclic RGD peptide

Mifune, Yuto,Nakamura, Hiroyuki,Fuse, Shinichiro

, p. 11244 - 11249 (2016/12/09)

A cyclic RGD peptide was efficiently synthesized based on micro-flow, triphosgene-mediated peptide chain elongation and micro-flow photochemical macrolactamization. Our approach enabled a rapid (amidation for peptide chain elongation 5 s, macrolactamization 5 min) and clean (only one column chromatographic separation) synthesis of a cyclic peptide.

Site-selective three-component reaction for dual-functionalization of peptides

Munch, Henrik K.,Rasmussen, Jakob E.,Popa, Gina,Christensen, J?rn B.,Jensen, Knud J.

supporting information, p. 1936 - 1938 (2013/04/10)

A site-selective dual-functionalization of peptides is presented, involving readily available maleimides as well as N-hydroxylamines. The modification proceeds through a three component 1,3-dipolar cycloaddition, forming a stable product. This was exemplified by the one-pot attachment of two molecular imaging moieties to a tumor binding cyclic peptide, and was extended to the conjugation of a DOTA chelator to a 12 kDa protein. The Royal Society of Chemistry 2013.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 161552-03-0